Determination of vancomycin pharmacokinetic/pharmacodynamic target and individualized dosing regimen recommendation in ICU neonates
Few studies incorporating population pharmacokinetic/pharmacodynamic (Pop-PK/PD) modelling have been conducted to quantify the exposure target of vancomycin in neonates. To determine this target and dosing recommendations, a retrospective observational cohort study was established in neonates (chictr.org.cn, ChiCTR1900027919). A Pop-PK model was developed to estimate PK parameters. Causalities between acute kidney injury (AKI) occurrence and vancomycin use were verified using Naranjo criteria. Thresholds of vancomycin exposure in predicting AKI or efficacy were identified via classification and regression tree analysis. Associations between exposure thresholds and clinical outcomes including AKI and efficacy, were analysed by logistic regression. Dosing recommendations were designed using Monte Carlo (MC) simulations based on the optimised exposure target. Pop-PK modelling included 182 neonates with 411 observations. In covariate analysis, neonatal physiological maturation, renal function, and concomitant use of vasoactive drugs (VAS) significantly affected vancomycin pharmacokinetics. Seven cases of vancomycin-induced AKI were detected. Area under the concentration-time curve from 0-24 h (AUC0-24) [≥] 485 mg*h/L was an independent risk factor for AKI after adjusting for VAS co-administration. Clinical efficacy of vancomycin was analysed in 42 patients with blood culture-proven staphylococcal sepsis. AUC0-24 to minimum inhibitory concentration (AUC0-24/MIC) [≥] 234 was the only significant predictor of clinical effectiveness. MC simulations indicated that regimens in Neonatal Formulary 7 and Red Book (2018) were not suitable for all neonates. In summary, AUC0-24 of 240-480 assuming MIC = 1 mg/L is a recommended exposure target of vancomycin in neonates. Model-informed dosing regimens are valuable in clinical practice.
- Downloaded 573 times
- Download rankings, all-time:
- Site-wide: 56,806
- In pharmacology and therapeutics: 64
- Year to date:
- Site-wide: 39,905
- Since beginning of last month:
- Site-wide: 38,708
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!